Regardless of who wins the White House and which party controls the House and Senate, the role of employer-sponsored health benefits is certain to get more attention in coming weeks….
Tonight begins the next phase of Campaign 2020 for the White House. Over the next four days, Democrats will stage their virtual 2020 National Convention culminating in the nomination of…
Last Thursday, Chicago-based Oak Street Health (OSH) became the latest healthcare services company to become a publicly traded corporation. Its underwriters set its share price at $21. Investors liked the…
The U.S. healthcare industry employs 16.8 million. In the pandemic, it is considered an “essential industry” among several considered necessary to managing the crisis. Its frontline workers in nursing homes…
Friday, the Value in Health Care Act of 2020 was introduced by U.S. Representatives Peter Welch, Suzan DelBene, and Darin LaHood. Its focus is the Medicare Shared Savings Program (MSSP)…
Medicare Advantage (MA) has been an option for seniors since 2003. By all accounts, it’s doing well: According to the Medicare Alliance, an advocacy group supportive of MA “With a…
Healthcare delivery in the U.S. is big business: annual spending for hospitals, physicians, allied health professionals, post-acute services and the prescriptions and tests they order represents almost 80% of the…
Last week, Gilead Sciences announced pricing for its breakthrough Covid-19 drug remdesivir (brand name Veklury) approved by the FDA for emergency use in May. The company announced it will charge…
Over the weekend, the impact of the coronavirus pandemic hit a staggering milestone: 10 million have been infected worldwide and 500,000 have died. In the U.S., infections exceed 2.5 million…
In a letter to Vice President Pence and House Speaker Pelosi last week, the Medicare Payment Advisory Commission conveyed its annual report to Congress: “Medicare and the Health Care Delivery…
Stay informed with Paul’s unique perspective on healthcare happenings, from policies and politics to innovations and investments. Subscribe today to the Keckley Report and be the first to receive Paul’s weekly insights and special reports.
© 2025 Paul Keckley.
